Plain-English translation of NCT07283692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new immunotherapy drug called combined with two chemotherapy medications ( and ) given before surgery in women with triple-negative breast cancer. The goal is to see if this combination treatment can shrink tumors and improve outcomes for patients with this aggressive type of breast cancer. Researchers want to know whether the new medication helps the body's immune system fight cancer cells more effectively.
Triple-negative breast cancer is a particularly aggressive form of the disease that doesn't respond to hormone-based treatments, making it harder to treat. This trial is exploring whether adding this immunotherapy medication to standard chemotherapy can improve how well treatment works and give patients better chances of survival.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the new immunotherapy medication along with two chemotherapy drugs through infusions, typically on a weekly schedule, before your cancer surgery. You would have regular clinic visits for treatment administration, blood tests to monitor your health and how your body is responding, and imaging scans to measure how the tumors are shrinking. After completing this medication phase, you would then proceed to surgery as planned by your cancer care team.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
RenJi Hospital
Enrollment target
~46 participants
Started
March 2026
Primary completion
December 2026
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenjin Yin, M.D.
Renji Hospital,School of Medicine, Shanghai Jiaotong University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.